In adults with type 2 diabetes and chronic kidney disease, taking a weekly 1.0 mg dose of semaglutide is associated with an 18% lower risk of major cardiovascular events compared to a placebo over...
Mechanism
Synthesis from 1 study
Semaglutide helps lower blood sugar and calm down harmful body-wide inflammation, which protects the blood vessels from damage. This makes it less likely for blockages to form or break loose in the heart or brain, reducing the risk of heart attacks and strokes.
Most probable mechanism
Semaglutide helps the body use insulin better and lowers blood sugar, which reduces damage to blood vessels. It also calms down harmful body-wide inflammation, making it less likely for plaques to form or break off in arteries, which lowers the chance of heart attacks and strokes.
Semaglutide activates glucagon-like peptide-1 receptors in pancreatic beta cells, increasing insulin secretion and reducing glucagon release, leading to improved glycemic control
Improved glycemic control reduces oxidative stress and endothelial dysfunction in blood vessels
Semaglutide reduces circulating levels of pro-inflammatory cytokines, decreasing vascular inflammation
Reduced vascular inflammation and improved endothelial function stabilize atherosclerotic plaques and decrease thrombotic events
Evidence from Studies
Supporting (1)
Community contributions welcome
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
Contradicting (0)
Community contributions welcome
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.